CD34+ CD105+ Mesenchymal Stem Cell Enrichment for Bone Therapy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for producing osteoprogenitors and bone-forming cells from mesenchymal stem cells (MSCs) are inefficient, with only a minor proportion contributing to bone tissue formation, and CD34-positive MSCs from bone marrow have not been described previously, lacking enhanced osteogenic and osteoregenerative properties.

Innovation Solution

Isolation and enrichment of MSCs from human bone marrow that co-express mesenchymal markers like CD105 and CD34, which exhibit high alkaline phosphatase levels and enhanced osteogenic potential, using haematopoietic and angiogenic growth factors such as FGF-2 to expand and differentiate these cells into bone-forming cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If conventional MSC transplantation is used to treat bone disorders, then bone tissue formation is achieved, but the yield of bone-forming cells is low because only a minor proportion of transplanted cells contribute to bone tissue formation

Engineering Contradiction:

Improveyield of bone-forming cellsVSAvoidproportion of cells contributing to bone tissue

Core Design Contradiction:

ProductivityVSQuantity of substance

Solution Approach 1:

The invention segments the heterogeneous MSC population by isolating and enriching for the specific CD34+CD105+CD90+ subset, separating the high osteogenic potential cells from the bulk MSC population that has limited bone-forming capacity

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The invention identifies and selects MSCs with specific local quality characteristics (CD34+, CD105+, CD90+ phenotype) that possess enhanced osteogenic properties, rather than treating all MSCs uniformly

Inventive Principle:

Principle #3Local quality

2Quantity of substance

If MSCs are isolated and expanded from bone marrow, then adequate quantities of cells can be obtained, but the osteogenic differentiation potential is variable and reduced

Engineering Contradiction:

Improvequantity of MSC cellsVSAvoidosteogenic differentiation potential

Core Design Contradiction:

Quantity of substanceVSReliability

Solution Approach 1:

The invention performs preliminary selection and enrichment of CD34+CD105+CD90+ MSCs before expansion to ensure that the cells with high osteogenic potential are isolated and maintained throughout the culture process

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The invention changes the selection parameters by using specific surface marker expression profiles (CD34+, CD105+, CD90+) to identify and isolate MSCs with enhanced and more reliable osteogenic differentiation potential

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentEP2291516B1Mesenchymal stem cells and bone-forming cells

Publication Date: 2019.01.02 BONE THRAPEUTICS SA

Figure 1
Figure 2
Figure 3

AI summary

The invention relates to a new type of mesenchymal stem cells (MSC) which co-express at least one mesenchymal marker, preferably at least CD105 and CD34. Also provided are bone-forming cells having an analogous phenotype. The invention also provides the cells and cell populations, as well as further products comprising such and uses thereof in bone therapy.